Table 1.
Demographic details of subjects included in the major intervention studies.
| 4S | WOSCOPS | CARE | AFCAPS/TEXCAPS | LIPID | |
|---|---|---|---|---|---|
| Primary or secondary | 2° | 1° | 2° | 1° | 2° |
| Number (active:placebo) | 2221:2223 | 3302:3293 | 2081:2078 | 3304:3301 | 4512:4502 |
| Drug | Simvastatin | Pravastatin | Pravastatin | Lovastatin | Pravastatin |
| Median duration (years) | 5.4 | 4.9 | 5.0 | 5.2 | 6.0 |
| Observed placebo CHD death rate† | 15.7 | 3.8 | 11.5 | 0.9 | 13.8 |
| Observed total mortality benefit† | 6.2 (CI 2.9, 9.4) | 1.8 (CI 0, 3.6) | 1.6 (CI −1.9, 5.0) | 0.2 (CI −1.6, 1.2) | 5.0 (CI 2.8, 7.3) |
| Mean age (years) | 58.5 | 55.2 | 59.0 | 58.3 | 62.3 |
| Proportion male (%) | 81.5 | 100 | 86 | 85 | 83 |
| Mean BP (mmHg) | 139/84 | 136/84 | 129/79 | 138/78 | * |
| % smokers | 25.5 | 44.0 | 21.0 | 12.5 | 10.0 |
| % diabetes | 4.5 | 1.0 | 14.5 | 2.5 | 9.0 |
| LDL (mmol l−1) | 4.87 | 4.96 | 3.59 | 3.89 | 3.88 |
| HDL (mmol l−1) | 1.18 | 1.14 | 1.01 | 0.95 | 0.93 |
| LDL/HDL ratio | 4.12 | 4.35 | 3.55 | 4.09 | 4.17 |
| Predicted CHD event rate† | 68.6 | 21.4 | 52.6 | 15.3 | 78.1 |
†
% over 10 years.
*
data not supplied.